Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions

Not Applicable

Completed

• Conditions: Hyperkalemia
• Interventions: Behavioral: decision support in potassium-inc. drug-drug-interactions

• Registration Number: NCT02020317
• Lead Sponsor: University of Zurich

Brief Summary

To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.

Detailed Description

The development of hyperkalemia during potassium-increasing drug-drug-interactions (DDIs) is associated with (i) unknown or elevated serum potassium level at onset of treatment and (ii) insufficient monitoring of serum potassium during therapy. However, potassium-increasing DDIs are frequently started despite an unknown or elevated serum potassium level, and monitoring intervals often exceed 48 hours.

This study investigates the impact of reminders for serum potassium monitoring and hyperkalemia alerts. Both reminders and alerts are displayed in the electronic patient chart of in-patients treated with potassium-increasing DDIs.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2013-12-12
• Study First Submitted QC: 2013-12-23
• Study First Posted: 2013-12-24
• Study Start: 2014-01
• Primary Completion: 2015-01
• Study Completion: 2015-01
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-05
• Last Update Posted: 2015-06-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3341

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
computer-based reminders and alerts	decision support in potassium-inc. drug-drug-interactions	Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)

Primary Outcome Measures

Name	Time	Method
Impact on serum potassium monitoring during potassium-increasing drug-drug-interactions	1 year	Rate of serum potassium monitoring intervals of \< = 72 hours during potassium-increasing drug-drug-interactions in proportion to all serum potassium monitoring intervals during potassium-increasing drug-drug-interactions

Secondary Outcome Measures

Name	Time	Method
Frequency of potassium-increasing drug-drug-interactions ordered in the presence of hyperkalemia	1 year
Frequency of transfers to the ICU during potassium-increasing drug-drug-interactions in function of the serum potassium level	1 year
Change in frequency distribution of serum potassium monitoring intervals	1 year
Frequency of hyperkalemia during potassium-increasing drug-drug-interactions	1 year
Response of physicians to the computer-based alerts and reminders	1 year
Frequency of death during potassium-increasing drug-drug-interactions in the presence or absence of hyperkalemia	1 year

Trial Locations

Locations (1)

University Hospital Zurich, Center for Clinical Research, Research Center for Medical Informatics; 🇨🇭 Zurich, ZH, Switzerland